No Nucynta Generics Until 2025, Fed. Circ. Affirms
A New Jersey federal judge rightly found that two patents covering Assertio Therapeutics Inc.'s Nucynta are valid and that a handful of generic-drug makers would infringe those patents if they move...To view the full article, register now.
Already a subscriber? Click here to view full article